AZELASTINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Azelastine Hydrochloride, and when can generic versions of Azelastine Hydrochloride launch?

Azelastine Hydrochloride is a drug marketed by Alembic, Apotex, Epic Pharma Llc, Gland, Sandoz, Somerset Theraps Llc, Sun Pharm, Alkem Labs Ltd, Amneal, Apotex Inc, Aurobindo Pharma Ltd, Bionpharma, Hikma, Padagis Israel, Padagis Us, Sciegen Pharms, Zydus Pharms, Aurobindo Pharma, and Teva Pharms Usa Inc. and is included in thirty NDAs.

The generic ingredient in AZELASTINE HYDROCHLORIDE is azelastine hydrochloride; fluticasone propionate. There are twelve drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the azelastine hydrochloride; fluticasone propionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azelastine Hydrochloride

A generic version of AZELASTINE HYDROCHLORIDE was approved as azelastine hydrochloride; fluticasone propionate by APOTEX on April 28^th, 2017.

Summary for AZELASTINE HYDROCHLORIDE

US Patents:	0
Applicants:	19
NDAs:	30
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AZELASTINE HYDROCHLORIDE

Paragraph IV (Patent) Challenges for AZELASTINE HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CHILDREN'S ASTEPRO ALLERGY	Nasal Spray	azelastine hydrochloride	205.5 mcg/spray	213872	1	2021-07-12
ASTEPRO	Nasal Spray	azelastine hydrochloride	205.5 mcg/spray	022203		2011-12-15
OPTIVAR	Ophthalmic Solution	azelastine hydrochloride	0.05%	021127	1	2006-12-13
ASTELIN	Nasal Spray	azelastine hydrochloride	0.125 mg base/spray	020114	1	2005-11-14

US Patents and Regulatory Information for AZELASTINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	207712-001	Apr 28, 2017	AB	RX	No	Yes
Padagis Israel	AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE	azelastine hydrochloride; fluticasone propionate	SPRAY, METERED;NASAL	208111-001	Feb 18, 2021	AB	RX	No	No
Alembic	AZELASTINE HYDROCHLORIDE	azelastine hydrochloride	SOLUTION/DROPS;OPHTHALMIC	209620-001	Mar 20, 2019	AT	RX	No	No

Investment Scenario and Fundamentals Analysis of AZELASTINE HYDROCHLORIDE

Last updated: February 21, 2026

What Is AZELASTINE HYDROCHLORIDE?

Azelastine hydrochloride is an antihistamine used primarily to treat allergic rhinitis and conjunctivitis. It functions as a potent H1 receptor antagonist, reducing allergy symptoms. The drug is marketed in various formulations: nasal spray, eye drops, and oral tablets.

Market Overview

Global Market Valuation and Growth Projections

• In 2022, the global allergic rhinitis treatment market was valued at approximately USD 6.5 billion.
• Compound annual growth rate (CAGR): projected at 4.5% from 2023 to 2030 (Grand View Research, 2022).
• Azelastine formulations hold an estimated 25% market share, with nasal spray remaining the dominant product form.

Key Players

• Meda AB (now part of Mylan, acquired by Pfizer)
• Mylan (now part of Viatris)
• Sandoz
• Sun Pharma
• Innovative generics companies in emerging markets

Patent Landscape

• Original patents for azelastine expired around 2018–2020 in major markets.
• Several countries have generic versions approved or in development.
• No recent patents have been filed, indicating a patent cliff for branded formulations.

Investment Fundamentals

Revenue Streams

• Predominantly driven by sales of nasal spray formulations; eye drops contribute to a smaller share.
• Growth driven by:
  • Expansion in emerging markets.
  • Increased allergy prevalence.
  • Rising demand for OTC antihistamines.

Cost Structure

• Manufacturing involves complex nasal spray technology but benefits from high-volume production.
• R&D costs are relatively low due to the drug's age and generic availability.
• Marketing costs focus on physician education and OTC channels.

Regulatory Environment

• Widely approved globally, including US FDA, EMA, and other authorities.
• Generic approval is straightforward post-patent expiry.
• Emerging markets show variable regulatory standards, offering both challenges and opportunities.

Competitive Position

• Mature, with high generic competition.
• Limited scope for new patent-protected formulations.
• Opportunities exist in formulation improvements or combination therapies.

Investment Risks

• Market saturation due to high generic competition.
• Price erosion pressures from multiple manufacturers.
• Regulatory changes affecting OTC and branded drug sales.
• Potential availability of newer allergy therapies.

Strategic Considerations

• Focus on geographic expansion, especially in fast-growing emerging markets.
• Invest in branding and education to differentiate in OTC segments.
• Explore formulation innovations or combination products.

Financial Metrics and Valuation

• Due to the generic status, profit margins are tight, typically around 20-30%.
• Companies with existing distribution channels and low manufacturing costs stand to benefit most.
• Market entry barriers are low; investing in established players among multiple generic manufacturers is a common strategy.

Key Takeaways

• AZELASTINE HYDROCHLORIDE faces significant generic competition following patent expiration.
• Growth hinges on geographic expansion and increased allergy incidence.
• The drug’s mature market limits high-margin opportunities but provides steady cash flow.
• Regulatory environments are stable worldwide but vary in emerging markets.
• Strategic investments should consider scaling manufacturing, distribution, and formulation innovation.

FAQs

What is the typical patent life remaining for azelastine?
Most patents expired or are expiring between 2018 and 2022, opening the market to generics.

Are there any ongoing patent disputes or legal challenges?
No significant current patent disputes are reported for azelastine in major markets.

What are the key regulatory hurdles in emerging markets?
Variable standards may require localized clinical data and certification, prolonging approval timelines.

Can azelastine formulations be combined with other drugs?
Yes. Combination therapies with other antihistamines or corticosteroids are being explored but are not yet widespread.

How does the competitive landscape impact pricing?
Intense competition drives prices downward, pressuring profit margins, especially in markets with multiple generic manufacturers.

References

1. Grand View Research. (2022). Allergic Rhinitis Treatment Market Size, Share & Trends Analysis Report.
2. U.S. Food and Drug Administration. (2020). Patent and exclusivity data for azelastine.
3. European Medicines Agency. (2021). Marketing authorization for azelastine formulations.
4. IMS Health. (2022). Global antihistamine market trend report.
5. World Health Organization. (2021). Global allergy prevalence and treatment trends.

Note: All figures are approximate estimates based on publicly available industry data as of 2023.